Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1974 participants.
Also called NCT02207634
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose other
- Phase
- Phase 3
- Enrolled
- 1,974 participants
- Sponsor
- Registry
-
NCT02207634 -
2014-001976-75
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Italy, Japan, Latvia, Lithuania, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Slovakia, South Africa, Spain, Sweden, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02207634. Randomized; quadruple masking; primary purpose other. Start 2014-09-10 (actual); primary completion 2016-11-11 (actual). Results posted on 2018-01-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
- Acronym
- EBBINGHAUS
- Condition
- Dyslipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Background Statin Therapy
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02207634- Content hash
5b4e735447acdd435da0e3fa769048c6f097c9f6454de2e458b4af183e9c876a